Richard MBBS - Kinnate Biopharma Chief Officer
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Insider
Richard MBBS is Chief Officer of Kinnate Biopharma
| Age | 55 |
| Phone | 858 299 4699 |
| Web | https://www.kinnate.com |
Kinnate Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.3363) % which means that it has lost $0.3363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.558) %, meaning that it created substantial loss on money invested by shareholders. Kinnate Biopharma's management efficiency ratios could be used to measure how well Kinnate Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Kinnate Biopharma currently holds 3.17 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Kinnate Biopharma has a current ratio of 22.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kinnate Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| CPA MS | Erasca Inc | 55 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Matthew Stanton | Generation Bio Co | 51 | |
| Charles Williams | Surrozen | 44 | |
| Mark Wallet | Century Therapeutics | N/A | |
| Jasbir Seehra | Keros Therapeutics | 68 | |
| Christopher MSc | Keros Therapeutics | 50 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Stewart Fisher | C4 Therapeutics | 57 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| MD FAAAAI | Palisade Bio | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Christopher Garcia | Surrozen | N/A | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Calvin MD | Surrozen | N/A | |
| MBA MD | Surrozen | 56 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
Management Performance
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 |
Kinnate Biopharma Leadership Team
Elected by the shareholders, the Kinnate Biopharma's board of directors comprises two types of representatives: Kinnate Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kinnate. The board's role is to monitor Kinnate Biopharma's management team and ensure that shareholders' interests are well served. Kinnate Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kinnate Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kania, Senior Research | ||
| Richard MBBS, Chief Officer | ||
| Jason MD, VP Quality | ||
| Neha Krishnamohan, Principal CFO | ||
| Barbara Warren, VP Culture | ||
| Mark Meltz, General COO | ||
| Nima MBA, CEO President | ||
| Priyanka Shah, VP Communications |
Kinnate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kinnate Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (25.71 M) | |||
| Shares Outstanding | 47.17 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 82.58 % | |||
| Number Of Shares Shorted | 465.63 K | |||
| Price To Book | 0.79 X | |||
| EBITDA | (118.21 M) | |||
| Net Income | (112.65 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |